Zobrazeno 1 - 8
of 8
pro vyhledávání: '"MFL Carvalho"'
IDENTIFICAÇÃO DE VULNERABILIDADES PARA INIBIÇÃO FARMACOLÓGICA DAS PIP4K2S EM LEUCEMIA MIELOIDE AGUDA
Autor:
K Lima, MFL Carvalho, DA Pereir-Martins, LBL Miranda, MCD Nascimento, FL Nogueira, RC Cavaglieri, JJ Schuringa, JA Machad-Neto, EM Rego
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S237- (2023)
Objetivo: As proteínas da família PIP4K2s (PIP4K2A, PIP4K2B e PIP4K2C) participam da geração do PIP4,5 P2 (PIP2), o qual atua como mensageiro secundário na transdução de sinal, substrato para processos metabólicos ou possui funções estrutur
Externí odkaz:
https://doaj.org/article/91c173eca4e548449c7f6ce600613e14
Autor:
K Lima, MFL Carvalho, DA Pereir-Martins, WF Silva, MCD Nascimento, LBL Miranda, RC Cavaglieri, L Nardinelli, AM Leal, EDRP Velloso, I Bendit, JJ Schuringa, JA Machad-Neto, EM Rego
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S236- (2023)
Objetivo: A leucemia linfoblástica aguda (LLA) do adulto é um grupo heterogêneo de neoplasias hematológicas altamente agressivas com altas taxas de recidiva e prognóstico ruim. A inibição farmacológica das proteínas da família fosfatidilino
Externí odkaz:
https://doaj.org/article/46caf85d7134464889946b3553e268b6
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S836-S837 (2023)
Objetivos: As neoplasias mieloides são resultantes de alterações moleculares na célula-tronco hematopoiética, sendo a leucemia mieloide aguda (LMA) a mais agressiva e com piores desfechos clínicos. O HCK é um proto-oncogene que codifica uma pr
Externí odkaz:
https://doaj.org/article/0a5bb133d7774d72afd04a9a25c16860
Autor:
Lima K; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: kelilima@usp.br., Nogueira FL; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Cipelli M; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Carvalho MFL; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Pereira-Martins DA; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil; Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., da Silva WF; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Cavaglieri RC; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Nardinelli L; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Leal AM; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Velloso EDRP; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Bendit I; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Câmara NOS; Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Schuringa JJ; Department of Experimental Hematology, Cancer Research Center Groningen, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Machado-Neto JA; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: jamachadoneto@usp.br., Rego EM; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil. Electronic address: eduardo.rego@fm.usp.br.
Publikováno v:
European journal of pharmacology [Eur J Pharmacol] 2024 Aug 15; Vol. 977, pp. 176723. Date of Electronic Publication: 2024 Jun 06.
Autor:
Carvalho MFL; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil., Calicchio CS; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil., de Almeida BO; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil., de Miranda LBL; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil., Lipreri da Silva JC; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil., Lima K; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil., Machado-Neto JA; Department of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address: jamachadoneto@usp.br.
Publikováno v:
Clinics (Sao Paulo, Brazil) [Clinics (Sao Paulo)] 2024 Jul 06; Vol. 79, pp. 100422. Date of Electronic Publication: 2024 Jul 06 (Print Publication: 2024).
Autor:
Carvalho MFL; Institute of Biomedical Sciences, University of São Paulo (USP), SP, Brazil., de Almeida BO; Institute of Biomedical Sciences, University of São Paulo (USP), SP, Brazil., Bueno MLP; Hematology and Transfusion Medicine Center, University of Campinas, Hemocentro-UNICAMP, Campinas, São Paulo, Brazil., Vicari HP; Institute of Biomedical Sciences, University of São Paulo (USP), SP, Brazil., Lima K; Institute of Biomedical Sciences, University of São Paulo (USP), SP, Brazil; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Rego EM; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil., Roversi FM; Hematology and Transfusion Medicine Center, University of Campinas, Hemocentro-UNICAMP, Campinas, São Paulo, Brazil; Department of Surgery Division Emory University, Atlanta, GA, USA., Machado-Neto JA; Institute of Biomedical Sciences, University of São Paulo (USP), SP, Brazil. Electronic address: jamachadoneto@usp.br.
Publikováno v:
Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2024 Jul-Sep; Vol. 46 (3), pp. 273-282. Date of Electronic Publication: 2023 Dec 31.
Autor:
Lima K; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil., Carvalho MFL; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil., Pereira-Martins DA; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.; Department of Experimental Hematology, University of Groningen, 9718 BG Groningen, The Netherlands., Nogueira FL; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil., de Miranda LBL; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil., Nascimento MCD; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil., Cavaglieri RC; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil., Schuringa JJ; Department of Experimental Hematology, University of Groningen, 9718 BG Groningen, The Netherlands., Machado-Neto JA; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil., Rego EM; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2023 Nov 29; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 29.
Autor:
Lipreri da Silva JC; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Carvalho MFL; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., de Miranda LBL; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., de Almeida BO; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Lima K; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil., Machado-Neto JA; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. jamachadoneto@usp.br.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2022 Aug; Vol. 40 (4), pp. 728-737. Date of Electronic Publication: 2022 Apr 28.